- Home
- CPT vs BMRN Comparison
CPT vs BMRN Comparison
Compare CPT & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPT | BMRN |
|---|---|---|
| Founded | 1993 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 12.3B |
| IPO Year | 1995 | 1999 |
Fundamental Metrics
Financial Performance| Metric | CPT | BMRN |
|---|---|---|
| Price | $99.93 | $56.34 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 24 | 28 |
| Target Price | ★ $112.83 | $91.59 |
| AVG Volume (30 Days) | 954.9K | ★ 2.1M |
| Earning Date | 11-05-2026 | 10-30-2026 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | ★ 136.00 | N/A |
| EPS | 0.59 | ★ 0.77 |
| Revenue | $12,967,000.00 | ★ $1,313,646,000.00 |
| Revenue This Year | N/A | $21.42 |
| Revenue Next Year | $0.91 | $14.51 |
| P/E Ratio | $166.05 | ★ $70.97 |
| Revenue Growth | ★ 81.69 | 17.62 |
| 52 Week Low | $95.30 | $49.26 |
| 52 Week High | $119.81 | $70.98 |
Technical Indicators
Market Signals| Indicator | CPT | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 43.42 | 31.35 |
| Support Level | $95.92 | $53.61 |
| Resistance Level | $106.13 | $57.95 |
| Average True Range (ATR) | 1.52 | 1.42 |
| MACD | 0.51 | -0.06 |
| Stochastic Oscillator | 71.01 | 11.06 |
Price Performance
Historical ComparisonAbout CPT Camden Property Trust
Camden Property Trust is a real estate investment trust engaged in the ownership, management, development, reposition, redevelopment, acquisition, and construction of multifamily apartment communities. It owned interests in, operated, or developing nearly 175 multifamily properties comprised of nearly 59,921 apartment homes across the United States.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.